Abstract

This is a proposal for institutional support of the McGill Cancer Centre and its adjunct clinical facilities for collaborative studies on cancer patients in association with Cancer and Leukemia Group B. It is proposed to participate in pilot, phase II and phase III multimodality studies of those hematologic and solid tumour malignancies where the greatest likelihood of substantial advances in long term remission and cure may be expected. State of the art modelling and pharmacologic concepts will be used. This program will be carried out in conjunction with CALGB using the established facilities of the McGill Cancer Centre and the five adjunct clinical facilities which include three tertiary care hospitals and two general hospitals. Emphasis will be placed on acute leukemia, lymphomas, breast and lung cancer. Active participation in all academic and administrative activities of CALGB is planned.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA031809-04
Application #
3557179
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-07-15
Project End
1987-03-31
Budget Start
1985-04-01
Budget End
1986-03-31
Support Year
4
Fiscal Year
1985
Total Cost
Indirect Cost

  Institution

Name
Mcgill University
Department
Type
DUNS #
City
Montreal
State
PQ
Country
Canada
Zip Code
H3 2T5

  Publications

Dressler, Lynn G; Berry, Donald A; Broadwater, Gloria et al. (2005) Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23:4287-97
Byrd, John C; Rai, Kanti; Peterson, Bercedis L et al. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53
Peters, William P; Rosner, Gary L; Vredenburgh, James J et al. (2005) Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA J Clin Oncol 23:2191-200
Muss, Hyman B; Woolf, Susan; Berry, Donald et al. (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-81
Peppercorn, Jeffrey; Herndon 2nd, James; Kornblith, Alice B et al. (2005) Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer 104:1580-9
Wetzler, Meir; Dodge, Richard K; Mrozek, Krzysztof et al. (2004) Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol 124:275-88
Farag, Sherif S; Ruppert, Amy S; Mrozek, Krzysztof et al. (2004) Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Int J Oncol 25:143-51
Silver, Richard T; Peterson, Bercedis L; Szatrowski, Ted P et al. (2003) Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leuk Lymphoma 44:39-48
Graziano, S L; Tatum, A; Herndon 2nd, J E et al. (2001) Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 33:115-23
Stone, R M; Berg, D T; George, S L et al. (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548-53

Showing the most recent 10 out of 22 publications